Top

Current Breast Cancer Reports

Published in:

01-12-2019 | Breast Cancer | Immuno-oncology (S Tolaney, Section Editor)

Combining Radiation Therapy with Immune Checkpoint Blockadein Breast Cancer

Authors: Shervin Tabrizi, Susan McDuff, Alice Y. Ho

Published in: Current Breast Cancer Reports | Issue 4/2019

Abstract

Purpose of Review

Immune checkpoint blockade (ICB) is an emerging therapy in breast cancer. Its optimal integration with radiation therapy (RT) for breast cancer remains to be established. Herein, we review the current evidence on combining ICB and RT in breast cancer and discuss the challenges, open questions, ongoing trials, and future directions for use of this treatment combination.

Recent Findings

Early trials of ICB in breast cancer show evidence of a modest response, limited due to the low baseline immunogenicity of most breast cancers. RT, as a potent stimulator of the immune system, has been used in combination with ICB with encouraging results. The optimal dose, fractionation, and timing of RT combined with ICB are active areas of investigation. Preclinical evidence suggests that moderate-dose, hypofractionated courses may be more effective at stimulating an immune response than high-dose, single-fraction courses.

Summary

Recent studies suggest that ICB can be active in breast cancer, but optimizing the response rate remains a challenge. The immunostimulatory effects of RT have the potential to overcome this obstacle, with promising data from preclinical and early clinical trials. Future investigation on the optimal dosing and fractionation of RT in combination with ICB will be critical.

FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer | FDA; 2019. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Accessed 2 Jun 2019.

•• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. https://doi.org/10.1056/nejmoa1809615. This study was a phase III, randomized trial of nab-paclitaxel with or without atezolizumab. Progression free survival benefit was observed in the PDL1-subset of nab-paclitaxel with atezolizumab. This led to the first FDA approval for ICB in metastatic triple negative breast cancer. CrossRefPubMed

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8. https://doi.org/10.1016/s0140-6736(18)32487-5.CrossRefPubMed

Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8. https://doi.org/10.1126/science.270.5238.985.CrossRefPubMed

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7. https://doi.org/10.1016/1074-7613(95)90125-6.CrossRefPubMed

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. https://doi.org/10.1111/j.1600-065x.2010.00923.x.CrossRefPubMedPubMedCentral

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331.CrossRefPubMed

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805. https://doi.org/10.1007/s10549-011-1554-7.CrossRefPubMed

Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol. 2015;1:448–54. https://doi.org/10.1001/jamaoncol.2015.0830.CrossRefPubMedPubMedCentral

10.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50. https://doi.org/10.1016/s1470-2045(17)30904-x.CrossRefPubMed

11.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7. https://doi.org/10.1200/jco.2011.41.0902.CrossRefPubMed

12.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66. https://doi.org/10.1200/jco.2013.55.0491.CrossRefPubMedPubMedCentral

13.

Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes. JAMA Oncol. 2016;2:1354. https://doi.org/10.1001/jamaoncol.2016.1061.CrossRefPubMed

14.

Sobral-Leite M, Van de Vijver K, Michaut M, et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1 -like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018;7:e1509820. https://doi.org/10.1080/2162402x.2018.1509820.CrossRefPubMedPubMedCentral

15.

Scott M, Scorer P, Barker C, Al-Masri H. 10OComparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol. 2019;30. https://doi.org/10.1093/annonc/mdz095.009.

16.

Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–7. https://doi.org/10.1200/jco.2015.64.8931.CrossRefPubMedPubMedCentral

17.

Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res. 2018;24:2804–11. https://doi.org/10.1158/1078-0432.ccr-17-3452.CrossRefPubMed

18.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:74. https://doi.org/10.1001/jamaoncol.2018.4224.CrossRefPubMed

19.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86. https://doi.org/10.1007/s10549-017-4537-5.CrossRefPubMed

20.

• Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20:371–82. https://doi.org/10.1016/s1470-2045(18)30812-x. This trial of trastuzumab and pembrolizumab in metastatic HER2+ breast cancer demonstrated that TIL levels greater than 5% was associated with a doubling of the response rate. CrossRefPubMed

21.

Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979;63:1229–35.PubMed

22.

Rieber M, Strasberg Rieber M. Sensitization to radiation-induced DNA damage accelerates loss of bcl-2 and increases apoptosis and autophagy. Cancer Biol Ther. 2008;7:1561–6. https://doi.org/10.4161/cbt.7.10.6540.CrossRefPubMed

23.

Rodriguez-Rocha H, Garcia-Garcia A, Panayiotidis MI, Franco R. DNA damage and autophagy. Mutat Res. 2011;711:158–66. https://doi.org/10.1016/j.mrfmmm.2011.03.007.CrossRefPubMedPubMedCentral

24.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9. https://doi.org/10.1038/nm1622.CrossRefPubMed

25.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. https://doi.org/10.1038/nm1523.CrossRefPubMed

26.

Surace L, Scheifinger NA, Gupta A, van den Broek M. Radiotherapy supports tumor-specific immunity by acute inflammation. Oncoimmunology. 2016;5:e1060391. https://doi.org/10.1080/2162402x.2015.1060391.CrossRefPubMed

27.

Lim JYH, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells. Cancer Immunol Immunother. 2014;63:259–71. https://doi.org/10.1007/s00262-013-1506-7.CrossRefPubMed

28.

Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488–96. https://doi.org/10.1158/0008-5472.can-10-2820.CrossRefPubMedPubMedCentral

29.

Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, van den Broek M. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology. 2012;1:1610–1. https://doi.org/10.4161/onci.21478.CrossRefPubMedPubMedCentral

30.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52. https://doi.org/10.1016/j.immuni.2014.10.019.CrossRefPubMedPubMedCentral

31.

Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830–42. https://doi.org/10.1016/j.immuni.2014.10.017.CrossRefPubMedPubMedCentral

32.

•• Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https://doi.org/10.1038/ncomms15618. This preclinical study demonstrated that release of cytosolic DNA following RT promotes an immune response. It also showed that relative to hypofractionated doses of RT, large, single fraction doses are associated with increased expression of the Trex1 endonuclease, which is associated with decreased cytosolic DNA and diminished immune response. This study established important preclinical rationale for RT fraction size and dose regimen when administered with ICB. CrossRefPubMedPubMedCentral

33.

Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462–70.PubMed

34.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516–23. https://doi.org/10.4049/jimmunol.174.12.7516.CrossRefPubMed

35.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN- production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132–9. https://doi.org/10.4049/jimmunol.180.5.3132.CrossRefPubMed

36.

Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589–602. https://doi.org/10.1016/j.ccr.2013.09.014.CrossRefPubMed

37.

Tsai C-S, Chen F-H, Wang C-C, Huang H-L, Jung S-M, Wu C-J, et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys. 2007;68:499–507. https://doi.org/10.1016/j.ijrobp.2007.01.041.CrossRefPubMed

38.

Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res. 2010;173:418–25. https://doi.org/10.1667/rr1860.1.CrossRefPubMedPubMedCentral

39.

Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181:3099–107. https://doi.org/10.4049/jimmunol.181.5.3099.CrossRefPubMed

40.

Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116:4558–66. https://doi.org/10.1073/pnas.1815515116.CrossRefPubMedPubMedCentral

41.

Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73:2782–94. https://doi.org/10.1158/0008-5472.can-12-3981.CrossRefPubMedPubMedCentral

42.

Komatsu N, Hori S. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A. 2007;104:8959–64. https://doi.org/10.1073/pnas.0702004104.CrossRefPubMedPubMedCentral

43.

Schaue D, Xie MW, Ratikan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol. 2012;2:90. https://doi.org/10.3389/fonc.2012.00090.CrossRefPubMedPubMedCentral

44.

Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. T _H 2-polarized CD4 ⁺ T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res. 2015;3:518–25. https://doi.org/10.1158/2326-6066.cir-14-0232.CrossRefPubMedPubMedCentral

45.

Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75:2232–42. https://doi.org/10.1158/0008-5472.can-14-3511.CrossRefPubMedPubMedCentral

46.

Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93:892–9. https://doi.org/10.1172/jci117045.CrossRefPubMedPubMedCentral

47.

Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, et al. TGF- blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci. 2012;109:16618–23. https://doi.org/10.1073/pnas.1117610109.CrossRefPubMedPubMedCentral

48.

Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, et al. TGFβ blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies. Mol Cancer Ther. 2019;18:621–31. https://doi.org/10.1158/1535-7163.mct-18-0558.CrossRefPubMed

49.

Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88. https://doi.org/10.1158/1078-0432.ccr-09-0265.CrossRefPubMedPubMedCentral

50.

Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655–66. https://doi.org/10.1016/j.ijrobp.2005.06.032.CrossRefPubMedPubMedCentral

51.

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95. https://doi.org/10.1172/jci67313.CrossRefPubMedPubMedCentral

52.

Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345–55. https://doi.org/10.1158/2326-6066.cir-14-0196.CrossRefPubMed

53.

Wu L, Wu MO, De la Maza L, Yun Z, Yu J, Zhao Y, et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget. 2015;6. https://doi.org/10.18632/oncotarget.3487.

54.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458–68. https://doi.org/10.1158/0008-5472.can-14-1258.CrossRefPubMed

55.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7. https://doi.org/10.1038/nature14292.CrossRefPubMed

56.

Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1:1325–32. https://doi.org/10.1001/jamaoncol.2015.2756.CrossRefPubMed

57.

Mole RH. Whole body irradiation—radiobiology or medicine? Br J Radiol. 1953;26:234–41. https://doi.org/10.1259/0007-1285-26-305-234.CrossRefPubMed

58.

Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503–10. https://doi.org/10.1016/j.ctrv.2015.03.011.CrossRefPubMedPubMedCentral

59.

Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728–34.PubMed

60.

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31. https://doi.org/10.1056/nejmoa1112824.CrossRefPubMedPubMedCentral

61.

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803. https://doi.org/10.1016/s1470-2045(15)00054-6.CrossRefPubMed

62.

Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. 2015;368:185–90. https://doi.org/10.1016/j.canlet.2015.03.024.CrossRefPubMed

63.

Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, et al. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int J Radiat Oncol. 2019;103:142–51. https://doi.org/10.1016/j.ijrobp.2018.09.010.CrossRef

64.

Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Investig. 2013;31:140–4. https://doi.org/10.3109/07357907.2012.762780.CrossRef

65.

Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol. 2019. https://doi.org/10.1038/s41571-019-0238-9.CrossRefPubMed

66.

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016;4:45. https://doi.org/10.1186/s40425-016-0149-6.CrossRefPubMedPubMedCentral

67.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol. 2013;86:343–9. https://doi.org/10.1016/j.ijrobp.2012.12.025.CrossRef

68.

Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589–95. https://doi.org/10.1182/blood-2009-02-206870.CrossRefPubMedPubMedCentral

69.

Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21:3727–39. https://doi.org/10.1158/1078-0432.ccr-14-2824.CrossRefPubMedPubMedCentral

70.

Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, et al. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8:e1523097. https://doi.org/10.1080/2162402x.2018.1523097.CrossRefPubMed

71.

Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med. 2012;4:137ra74. https://doi.org/10.1126/scitranslmed.3003649.CrossRefPubMed

72.

Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028. https://doi.org/10.1080/2162402x.2015.1046028.CrossRefPubMedPubMedCentral

73.

Markovsky E, Budhu S, Samstein RM, Li H, Russell J, Zhang Z, et al. An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models. Int J Radiat Oncol. 2019;103:697–708. https://doi.org/10.1016/j.ijrobp.2018.10.009.CrossRef

74.

• Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36:1611–8. https://doi.org/10.1200/jco.2017.76.2229. This phase II trial included multiple tumor types treated with SBRT in combination with pembrolizumab for solid tumors. Only 8% of patients in this trial had breast cancer. CrossRefPubMedPubMedCentral

75.

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One. 2016;11:e0157164. https://doi.org/10.1371/journal.pone.0157164.CrossRefPubMedPubMedCentral

76.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–8. https://doi.org/10.1038/s41591-019-0432-4.CrossRefPubMed

77.

Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20:e175–86. https://doi.org/10.1016/s1470-2045(19)30026-9.CrossRefPubMed

78.

McArthur HL, Barker CA, Gucalp A, Lebron-Zapata L, Wen YH, Phung A, et al. A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 2018;36:14. https://doi.org/10.1200/jco.2018.36.5_suppl.14.CrossRef

79.

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03051672. Accessed 10 Jun 2019.

80.

McArthur H, Beal K, Halpenny D, et al. Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM). In: Immunology. Philadelphia: American Association for Cancer Research; 2017. p. 4705.CrossRef

81.

Jiang DM, Fyles A, Nguyen LT, Neel BG, Sacher A, Rottapel R, et al. Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. Oncotarget. 2019;10:2947–58. https://doi.org/10.18632/oncotarget.26893.CrossRefPubMed

82.

Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–86. https://doi.org/10.1038/nrclinonc.2016.58.CrossRefPubMed

83.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003.CrossRefPubMed

84.

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569:428–32. https://doi.org/10.1038/s41586-019-1162-y.CrossRefPubMed

85.

Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15:477–94. https://doi.org/10.1038/s41571-018-0046-7.CrossRefPubMed

86.

Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, et al. Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol. 2018;4:1123–4. https://doi.org/10.1001/jamaoncol.2017.3993.CrossRefPubMedPubMedCentral

87.

Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, et al. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neuro-Oncol. 2017;133:595–602. https://doi.org/10.1007/s11060-017-2470-4.CrossRef

88.

Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg. 2016;125:17–23. https://doi.org/10.3171/2015.6.jns142763.CrossRefPubMed

89.

Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, et al. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg. 2018;129:1397–406. https://doi.org/10.3171/2017.7.jns171286.CrossRefPubMedPubMedCentral

90.

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03464942. Accessed 6 Jun 2019.

91.

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03483012. Accessed 6 Jun 2019.

92.

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03449238. Accessed 6 Jun 2019.

93.

Cardoso F, Bardia A, Andre F, et al. Abstract OT3-04-03: KEYNOTE-756: a randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER ⁺ /HER2 ⁻ breast cancer. In: Ongoing Clin. Trials. Philadelphia: American Association for Cancer Research; 2019. p. OT3-04-03-OT3-04–03.

94.

Pusztai L, Barlow W, Ganz P, et al. Abstract OT1-02-04: SWOG S1418/NRG -BR006: a randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. In: Ongoing Clin. Trials. Philadelphia: American Association for Cancer Research; 2018. p. OT1–02-04-OT1–02–04.

95.

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03818685. Accessed 6 Jun 2019.

96.

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/− Durvalumab, +/− Oleclumab in Luminal B Breast Cancer: - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03875573. Accessed 6 Jun 2019.

97.

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/− RAdiation Therapy in Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03872505. Accessed 6 Jun 2019.

Title: Combining Radiation Therapy with Immune Checkpoint Blockadein Breast Cancer
Authors: Shervin Tabrizi
Susan McDuff
Alice Y. Ho
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Current Breast Cancer Reports / Issue 4/2019
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-019-00327-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

The Promise of Immunotherapy for Breast Cancer Brain Metastases

Combination Immunotherapy Strategies in Breast Cancer

Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy

Updates in Genetic Testing Guidelines for Breast Cancer Susceptibility Genes: a Change in the Paradigm

Preoperative Radiotherapy Trials to Facilitate Immediate Breast Reconstruction after Mastectomy

I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer